IMR Press / RCM / Special Issues / 1617687400166

Drug-Coated balloons-The “leave nothing behind” strategy

Submission deadline: 30 September 2021
Special Issue Editors
Bernardo Cortese
Cardiovascular Research Team, San Carlo Clinic, Milan, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy
Interests: Percutaneous tricuspid interventions; Conduction disturbances after TAVI; Antithrombotic therapy in TAVI patients; Percutaneous treatment of bicuspid valve
Special Issue Information

Dear Colleagues,

 

Interventional cardiology is evolving rapidly with an increased need for better results in treatment of coronary artery disease (CAD) which is the leading cause of death worldwide.
The introduction of drug eluting stents (DES) revolutionized treatment of coronary artery disease by reducing the rate of restenosis to 5%-10%. However, the use of DES in complex patients such as diabetic, small vessel disease, long lesions and coronary artery bypass grafting is still associated with higher risk of ISR.
In recent years, drug-coated balloons (DCB) have emerged as a potential alternative to combat restenosis and fulfill the goal of the DES without duplicating the limitations encountered with previously available devices. With currently available paclitaxel and sirolimus balloon coatings DCBs are showing non-inferiority vs DES in different patient settings. However, a major challenge in the management of coronary artery disease is the accurate identification of those patients who will benefit from either DCB or DES and which coating outperforms the other at long term.

Importance
CAD has an increasing incidence, prevalence and mortality rate. In light of recent advances in various delivering and coating devices for management of CAD we introduce this series of concise reviews that will focus on the contemporary management of these patients and investigate different approaches of their care.

 

Dr. Bernardo Cortese

Guest Editor

Keywords
DCB
Paclitaxel
Sirolimus
Chip patients
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://jour.ipublishment.com/imr/access/login by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted papers should be well formatted and use good English.

Published Paper (5 Papers)
Open Access Review
Drug-coated balloon for the management of coronary chronic total occlusions
Erick Sanchez-Jimenez, Rami El-Mokdad, Rima Chaddad, Bernardo Cortese
Rev. Cardiovasc. Med. 2022, 23(2), 42; https://doi.org/10.31083/j.rcm2302042
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
10
Download
18
Views
Open Access Review
DCBs as an adjuvant tool to DES for very complex coronary lesions
Rima Chaddad, Rami El-Mokdad, Leontin Lazar, Bernardo Cortese
Rev. Cardiovasc. Med. 2022, 23(1), 13; https://doi.org/10.31083/j.rcm2301013
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
10
Download
109
Views
Open Access Review
Is a high calcific burden an indication, or a contraindication for Drug Coated Balloon?
Sandeep Basavarajaiah, Bhagya Harindi Loku Waduge, Richard Watkin, Sampath Athukorala
Rev. Cardiovasc. Med. 2021, 22(4), 1087–1093; https://doi.org/10.31083/j.rcm2204120
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
27
Download
61
Views
Open Access Review
Should paclitaxel be considered an old generation DCB? The limus era
Gaetano di Palma, Erick Francisco Sanchez-Jimenez, Leontin Lazar, Bernardo Cortese
Rev. Cardiovasc. Med. 2021, 22(4), 1323–1330; https://doi.org/10.31083/j.rcm2204138
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
19
Download
39
Views
Open Access Review
Back to the future: the role of DCB for the treatment of coronary bifurcation
Andrea Buono, Diego Maffeo, Mariano Pellicano, Giuseppe De Blasio, ... Alfonso Ielasi
Rev. Cardiovasc. Med. 2021, 22(4), 1421–1428; https://doi.org/10.31083/j.rcm2204147
(This article belongs to the Special Issue Drug-Coated balloons-The “leave nothing behind” strategy)
30
Download
53
Views
Back to top